

# Keystone Symposia 2017 Conference Series

## **Cell Plasticity within the Tumor Microenvironment (A1)**

January 8–12, 2017 | Big Sky, Montana | USA

## **Precision Genome Engineering (A2)**

Jan 8–12, 2017 | Breckenridge, Colorado | USA

## **Transcriptional & Epigenetic Control in Stem Cells (J1)**

*joint with Neurogenesis during Development & in the Adult Brain (J2)*

Jan 8–12, 2017 | Olympic Valley, California | USA

## **TGF- $\beta$ in Immunity, Inflammation & Cancer (A3)**

January 9–13, 2017 | Taos, New Mexico | USA

## **Mitochondria Communication (A4)**

January 14–18, 2017 | Taos, New Mexico | USA

## **New Developments in Our Basic Understanding of Tuberculosis (A5)**

January 14–18, 2017 | Vancouver, British Columbia | Canada

## **PI3K Pathways in Immunology, Growth Disorders & Cancer (A6)**

Jan 19–23, 2017 | Santa Fe, New Mexico | USA

## **Biobetters & Next-Generation Biologics:**

### **Innovative Strategies for Optimally Effective Therapies (A7)**

Jan 22–26, 2017 | Snowbird, Utah | USA

## **Diabetes (J3) *joint with Obesity & Adipose Tissue Biology (J4)***

January 22–26, 2017 | Keystone, Colorado | USA

## **Omics Strategies to Study the Proteome (A8)**

January 29–February 2, 2017 | Breckenridge, Colorado | USA

## **Epigenetics & Human Disease:**

### **Progress from Mechanisms to Therapeutics (A9)**

January 29–February 2, 2017 | Seattle, Washington | USA

## **Hematopoiesis (B1)**

January 31–February 4, 2017 | Banff, Alberta | Canada

## **Noncoding RNAs: From Disease to Targeted Therapeutics (J5)**

*joint with Protein-RNA Interactions: Scale, Mechanisms, Structure & Function of Coding & Noncoding RNPs (J6)*

February 5–9, 2017 | Banff, Alberta | Canada

## **Inflammation-Driven Cancer: Mechanisms to Therapy (J7)**

*joint with Microbiome in Health & Disease (J8)*

February 5–9, 2017 | Keystone, Colorado | USA

## **Autophagy Network Integration in Health & Disease (B2)**

February 12–16, 2017 | Copper Mountain, Colorado | USA

## **Asthma: From Pathway Biology to Precision Therapeutics (B3)**

February 12–16, 2017 | Keystone, Colorado | USA

## **Viral Immunity: Mechanisms & Consequences (B4)**

February 19–23, 2017 | Santa Fe, New Mexico | USA

## **Malaria: From Innovation to Eradication (B5)**

February 19–23, 2017 | Kampala | Uganda

## **Lipidomics & Bioactive Lipids in Metabolism & Disease (B6)**

February 26–March 2, 2017 | Tahoe City, California | USA

## **Bile Acid Receptors as Signal Integrators in Liver & Metabolism (C1)**

March 3–7, 2017 | Monterey, California | USA

## **Rare & Undiagnosed Diseases:**

### **Discovery & Models of Precision Therapy (C2)**

March 5–8, 2017 | Boston, Massachusetts | USA

## **mRNA Processing & Human Disease (C3)**

March 5–8, 2017 | Taos, New Mexico | USA

## **Synapses & Circuits: Formation, Function & Dysfunction (X1)**

*joint with Connectomics (X2)*

March 5–8, 2017 | Santa Fe, New Mexico | US

## **Tumor Metabolism: Mechanisms & Targets (X3)**

*joint with Adaptations to Hypoxia in Physiology & Disease (X4)*

March 5–9, 2017 | Whistler, British Columbia | Canada

## **Engineered Cells & Tissues as Platforms for Discovery & Therapy (K1)**

March 9–12, 2017 | Boston, Massachusetts | USA

## **Kinases: Next-Generation Insights & Approaches (C4)**

March 5–9, 2017 | Breckenridge, Colorado | USA

## **Frontiers of NMR in Life Sciences (C5)**

March 12–16, 2017 | Keystone, Colorado | USA

## **Sex & Gender Factors Affecting Metabolic Homeostasis, Diabetes & Obesity (C6)**

March 19–22, 2017 | Tahoe City, California | USA

## **Cancer Immunology & Immunotherapy:**

### **Taking a Place in Mainstream Oncology (C7)**

March 19–23, 2017 | Whistler, British Columbia | Canada

## **Pattern Recognition Signaling: From Innate Immunity to Inflammatory Disease (X5) *joint with Type I Interferon: Friend & Foe Alike (X6)***

March 19–23, 2017 | Banff, Alberta | Canada

## **Injury, Inflammation & Fibrosis (C8)**

March 26–30, 2017 | Snowbird, Utah | USA

## **HIV Vaccines (C9)**

March 26–30, 2017 | Steamboat Springs, Colorado | USA

## **Immune Regulation in Autoimmunity & Cancer (D1)**

March 26–30, 2017 | Whistler, British Columbia | Canada

## **Molecular Mechanisms of Heart Development (X7)**

*joint with RNA-Based Approaches in Cardiovascular Disease (X8)*

March 26–30, 2017 | Keystone, Colorado | USA

## **Genomic Instability & DNA Repair (Z1)**

*joint with DNA Replication & Recombination (Z2)*

April 2–6, 2017 | Santa Fe, New Mexico | USA

## **B Cells & T Follicular Helper Cells: Controlling Long-Lived Immunity (D2)**

April 23–27, 2017 | Whistler, British Columbia | Canada

## **Mononuclear Phagocytes in Health, Immune Defense & Disease (D3)**

April 30–May 4, 2017 | Austin, Texas | USA

## **Modeling Viral Infections & Immunity (E1)**

May 1–4, 2017 | Estes Park, Colorado | USA

## **Angiogenesis & Vascular Disease (Z3)**

*joint with Mitochondria, Metabolism & Heart (Z4)*

May 8–12, 2017 | Santa Fe, New Mexico | USA

## **Neuronal Control of Appetite, Metabolism & Weight (Z5)**

*joint with Gastrointestinal Control of Metabolism (Z6)*

May 9–13, 2017 | Copenhagen | Denmark

## **Aging & Mechanisms of Aging-Related Disease (E2)**

May 15–19, 2017 | Yokohama | Japan

## **Single Cell Omics (E3)**

May 26–30, 2017 | Stockholm | Sweden

## **Integrating Metabolism & Immunity (E4)**

*joint with Cell Death & Inflammation (K2)*

May 29–June 2, 2017 | Dublin | Ireland

## **Vectors, Pathogens & Diseases: Current Trends & Emerging Challenges (T1)**

September 10–14, 2017 | Durban, KwaZulu-Natal | South Africa

## **Maternal-Fetal Cross Talk: Harmony vs. Conflict (T2)**

October 4–8, 2017 | Washington, DC | USA

## **Regenerative Biology & Applications: Cell Differentiation, Tissue Organization & Biomedical Engineering (T3)**

October 15–19, 2017 | Pok Fu Lam, Hong Kong | China

## **Antimicrobials and Resistance: Opportunities and Challenges (T4)**

October 29–November 1, 2017 | Santa Fe, New Mexico | USA

## **Frontiers of Serotonin Beyond the Brain (T5)**

November 12–15, 2017 | Park City, Utah | USA

Abstract and discounted registration deadlines are three months and two months, respectively, before conferences begin. Abstracts submitted by the abstract deadline will be considered for short talks on the program. Information shown subject to possible change.

[www.keystonesymposia.org/meetings](http://www.keystonesymposia.org/meetings) | 1.800.253.0685 | 1.970.262.1230

KEYSTONE SYMPOSIA™  
on Molecular and Cellular Biology  
Accelerating Life Science Discovery